More than $2 billion will be spent by Scripps Health over the coming twenty five years to restore and enlarge its La Jolla hospital, the nonprofit had said.

The 389-bed hospital of Scripps will be replaced with 3 new hospital towers to comply with earthquake safety standards of the state. Space for graduate medical education and research will also be provided by it.

On the first tower, construction is planned to commence in June, and in 2015 it is to open. The 383,000-square-foot, eight-story tower will cost $398 million. 60 intensive care beds, 108 private beds, cardiac catheterization, six operating rooms and cardiovascular research labs will be present.

The project includes, in addition to the three towers, an outpatient care pavilion, new medical office buildings and more parking. Services will include robotic surgery, wireless technology, record-keeping and digital monitoring, Scripps has said in a news release.

To the city of San Diego, Scripps has submitted the plan, which is now being reviewed.

In the region several hospitals have started with other projects of large-scale expansion. In addition to meeting standards for earthquakes, also offered are upgraded services by the expansions to better compete for patients.

– Nearly $1 billion is spent by Palomar Pomerado Health for the construction of a new hospital complex near its border in Escondido with San Marcos. The Palomar Medical Center will be replaced by the hospital in downtown Escondido.

– In April UC San Diego has made it known that it will construct a hospital complex costing $664 million at the La Jolla east campus of the University. The complex with 245 beds will include 3 hospitals, one each for cancer patients, advanced surgery, and for infants and women and will be completed in 2016.

– $194 million had been spent by Sharp Memorial Hospital on its latest “hospital of the future,” that had been opened in 2009 February.

The East Syracuse campus of Bristol Myers Squibb is more than 60 years old. The pharmaceutical manufacturing facility, launched in 1943, produced nearly seventy percent of the penicillin until the mid 2000s produced in the world. A two-phase project started last year is in progress to transform the site into a park-type biotech research centre from a penicillin-manufacturing facility, in agreement with the company’s strategy overall. In 2013 the first phase is planned to finish.

Nearly two years will be taken by the project to be completed. The pulling down of half of the buildings will be seen on the campus, which have remained idle and become obsolete since production of penicillin was phased out in mid-2000s. Over ten million dollars is the expected cost of the project. Hueber-Breuer Construction Co. is the lead contractor for the project.

The facility for decades has made a bulk active antibiotic that is part of the active pharmaceutical ingredient for creating penicillin. In the last decade, however, the operations of the facility have changed to developing biologics manufacturing processes for biologics, or medicines made from animal and plant-derived cells.

The facility has the competence to produce biologic medicines for commercial drug launch and for clinical trials. Production at a full-scale in smaller volumes can be carried out in the Syracuse facility. At other Bristol Myers facilities production at a large-scale will be carried out.

The Syracuse facility develops biologics in highly controlled environments by growing plant or animal-derived cells. The cells are mixed with oxygen and nutrients in the correct amount and set aside for the right time limit at the right pH and temperature. During the procedure, proteins are produced by the cells that are harvested and purified. These are made into biologic drugs which take care of a host of diseases that include diabetes, arthritis and cancer.

Involving four organizations, the UK Centre for Medical Research and Innovation with the Medical Research Council, Cancer Research UK, the Wellcome Trust and University College London is a biomedical research partnership. It will rank among the largest in the world as the first biomedical research facility in the UK in terms of size, placed after only Pasteur Institute that is Paris-based.

The future facility in London will be constructed north of the British Library, at Brill Place. By early 2011, work on the facility is anticipated to begin with a late 2014 completion. In 2015, operations are scheduled to begin.

The facility will be built over a site of 3.6 acres. The facility’s main body will be a characteristic, glass atrium with four storeys that will enable the public to watch the progressing research.

More or less one-third of the facility, to reduce scale, will be underground. Also its vaulted roof will be separated into 2 shells in the place of a single span.

The facility will be approximately staffed by 1,250 scientists, who are a part of the 1,500 people to be taken in. It has an expenditure of £600m ($887m) to build, and an added £100m for operations.

The facility will carry out research and utilize the most modern technology to extend fresh treatments for a variety of diseases, including cancer, heart diseases, flu and stroke. Animal research will also be undertaken.

Nevertheless, the facility will not conduct the category four researches or take on clinical research that is presently being conducted at NIMR. By collaborating with other research centres and hospitals, Clinical research will be done.

Construction cost of about fifty percent will be borne by the Medical Research Council of UK. About 5-10% of the cost of the project will be contributed by University College London, Cancer Research UK 25-30% and the Wellcome Trust 20%.

Through a blend of sources the facility will be funded, including charitable organizations and the UK Government. As construction progresses, provided in a phased manner, Government funding will be in the region of £250m, over the next 5 years.

Project managing the facility is Arup, who will also provide mechanical and electrical engineering services along with HOK Architects. Adams Kara Taylor has been awarded with the contract for the structural engineering of the project.